- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2016–2021 · program · P01
Comprehensive dissection of the CLL genome and phenome to improve patient outcomes
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · program · P01
Comprehensive dissection of the CLL genome and phenome to improve patient outcomes
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
Identifying causal variants and genes underlying breast cancer risk loci
Matthew L Freedman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R50
Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human Cancer
Gregory Howard Bird · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
A. Thomas Look · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · research · R01
Humanized bone marrow-like model to study patient-derived myeloma xenografts
Richard Groen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Comprehensive dissection of the CLL genome & phenome to improve patient outcomes
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2017 · award
Overcoming Resistance in BCR-ABL-Rearranged Acute Lymphoblastic Leukemia
Mark Murakami · Dana-Farber Cancer Institute · funded by American Cancer Society
2016–2019 · research · R01
Computational Methods for Genome-Wide CRISPR Screens
Xiaole Shirley Liu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2020 · grant · BCRP
Dissecting the Mechanisms of Drug Resistance in BRCA1/2-Mutant Breast Cancers
Alan D'Andrea · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2016–2021 · research · R01
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)
Irene M. Ghobrial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2020 · research · R01
Organizational Approaches to Total Worker Health for Low-Income Workers
Glorian C Sorensen · Dana-Farber Cancer Institute · funded by National Institute for Occupational Safety and Health
2016–2021 · career development · K08
Chemotherapy resistance induced by SETD2 loss in leukemia
Brenton G Mar · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016 · fellowship · CIHR Fellowship
Engineering a nanofactory for cytosolic manufacturing of shRNA in living cells
Leo Chou · Dana-Farber Cancer Institute · funded by Canadian Institutes of Health Research
2016–2021 · research · R01
Novel functions of D-type and E-type cyclins in normal and in cancer cells
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · research · R01
Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate Cancer
Christopher J Sweeney · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · program · P01
Comprehensive dissection of the CLL genome and phenome to improve patient outcomes
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
New Paradigms for Targeting Truncal Driver Mutations
William G. Kaelin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2031 · research · R35
Role of Phosphoinositides and Protein Kinases in the control of Cancer Metabolism
Lewis C. Cantley · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
Rani E. George · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2022 · training · T32
Cancer Immunology Training Grant
Kai W Wucherpfennig · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
(PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy
Rosalind A. Segal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016 · research · Former Investigator Profile
Levi A. Garraway, MD — HHMI Former Investigator Profile (2016-2016)
Levi A. Garraway, Md · Dana-Farber Cancer Institute · funded by Howard Hughes Medical Institute
2016–2018 · research · R03
CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors
Christopher John Recklitis · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
Conformational Landscape of the HIV-1 Envelope Glycoproteins
Joseph G Sodroski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
Kimberly Stegmaier · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · cooperative agreement · U01
Circulating Biomarker Consortium for Pancreatic Cancer Early Detection
Brian Matthew Wolpin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · research · R00
The Role of EglN1 and HIF in Normal Hematopoiesis and in Leukemia
Julie-Aurore Losman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · career development · K08
Determining the Role of BCOR Mutations in Myeloid Malignancies
Robert Coleman Lindsley · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2022 · career development · K00
The role of CMTR2 in Lung Cancer
Alena Yermalovich · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · research · R01
Conformational Landscape of the HIV-1 Envelope Glycoproteins
Joseph G Sodroski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
Kimberly Stegmaier · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · research · R50
Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human Cancer
Gregory Howard Bird · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)
Irene M. Ghobrial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · research · R50
Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human Cancer
Gregory Howard Bird · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · career development · K08
The mechanism of DNA damage and chromothripsis from chromosome segregation errors
Alexander Spektor · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · fellowship · F31
Dissecting the Mitochondrial Translocation Mechanism of Anti-Apoptotic BCL-w
Edward Paul Harvey · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · research · R01
Conformational Landscape of the HIV-1 Envelope Glycoproteins
Joseph G Sodroski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer
Jean Zhao · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R50
Immunogenomic analytical approaches for research and clinical applications
Sachet Ashok Shukla · Dana-Farber Cancer Institute · funded by National Institutes of Health
